获得性免疫缺陷综合征相关原发性中枢神经系统淋巴瘤的预后研究

doi:10.3877/cma.j.issn.1674-1358.2023.03.009

目的

构建获得性免疫缺陷综合征（AIDS）相关原发性中枢神经系统淋巴瘤（AR-PCNSL）的短期预后生存分析模型并进行内部验证。

方法

由首都医科大学附属北京地坛医院电子病例系统中收集2013年1月至2022年3月经病理确诊的42例AR-PCNSL患者组成1个回顾性队列，死亡为终点事件，主要评价指标为总体生存率（OS），通过单因素Cox回归分析筛选与OS相关因素，构建多因素Cox生存分析模型并绘制列线图，模型区分度和准确度分别用C指数和校准曲线评价（采用bootstrap重抽样1 000次的方法绘制）。生存资料采用Kaplan-Meier法进行生存分析和log_rank检验。

结果

42例患者年龄为[34（28，51）]岁，其中男性39例（93%）。17例（40.5%）患者出现死亡终点，中位生存时间未达到，中位随访时间为945（230，1518）d。Karnofsky功能状况评分（KPS）（HR = 0.27、95%CI：0.073~1.0、P = 0.012）和深部脑结构受累（HR = 2.42、95%CI：1.747~7.8、P = 0.040）两个变量纳入多因素Cox回归分析构建预后模型，C指数为0.72，预测校准曲线与理想曲线接近。根据列线图得分的三分位数进行危险分层，低、中风险组生存曲线交叉，与高风险组生存曲线无交叉（P = 0.0023）。

结论

KPS低于70分、深部脑结构受累是影响AR-PCNSL预后的危险因素，基于二者Cox回归分析模型区分度一般但预测准确性高，仍需要进一步优化。

关键词: 获得性免疫缺陷综合征, 原发性中枢神经系统淋巴瘤, Cox生存分析, 预后

Objective

To develop and validate a short-term prognostic model of acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (AR-PCNSL).

Methods

Total of 42 patients confirmed AR-PCNSL pathologically were enrolled retrospectively from January, 2013 to March, 2022 in Beijing Ditan Hospital, Capital Medical University. The primary endpoint was overall survival (OS). Clinical variables associated with survival were assessed based on clinical importance scientific knowledge, and predictors identified in previously published article. The prognostic factors included in multivariate Cox regression analysis were used to develop a predicted model and a nomogram was established accordingly. The discrimination of the model were evaluated by C index and 1 000 bootstrapped resampling to qualify any overfitting. Survival data were analyzed by Kaplan-Meier survival analysis and log_rank test.

Results

The age of 42 patients was [34 (28, 51)] years old; 93% (39/42) patients were male; 40.5% (17/42) patients died due to AR-PCNSL terminal period, and the median survival time was not available. The median follow-up time were [945 (230, 1518)] days. Karnofsky Performance Status (KPS) score (HR = 0.27, 95%CI: 0.073-1.0, P = 0.012) and deep brain structure (HR = 2.42, 95%CI: 1.747-7.8, P = 0.040) were included in multivariate Cox regression analysis to fit a prognostic model with C index 0.72, and the predicted calibration curve was close to the ideal curve. Risk was stratified according to the tertiles of the nomogram scores. The Kaplan-Meier curves of the low and medium risk groups crossed partially, but paralleled with the high risk group (P = 0.0023).

Conclusions

KPS lower than 70, deep brain structure involvement are two risk factors for AR-PCNSL patients to effectively predict the individual short-term mortality risk. The Cox regression model with moderate discrimination and accurate prediction needs to be optimized further.

Key words: Acquired immune deficiency syndrome, Primary central nervous system lymphoma, Cox regression analysis, Prognosis

图1 AR-PCNSL患者的筛选流程图

表1 AR-PCNSL患者的临床与影像学特征

临床与影像学特征	数值
主诉时间[M（P25，P75），d]	30（10，60）
KPS评分≥ 70 [例（%）]	19（45.2）
CD4⁺ T淋巴细胞计数[M（P25，P75），个/ml]	37（7，149）
HIV载量[M（P25，P75），log拷贝/μl]	9.8（4.7，11.7）
既往HARRT治疗[例（%）]	25（59.5）
血清LDH水平升高[例（%）]	15（35.7）
脑脊液蛋白含量升高[例（%）]	32（76.2）
DLBCL [例（%）]	29（69.0）
深部脑结构受累[例（%）]	22（52.4）
颅内多发病灶[例（%）]	26（61.9）
确诊后放化疗[例（%）]	22（52.4）

表1 AR-PCNSL患者的临床与影像学特征

临床与影像学特征	数值
主诉时间[M（P25，P75），d]	30（10，60）
KPS评分≥ 70 [例（%）]	19（45.2）
CD4⁺ T淋巴细胞计数[M（P25，P75），个/ml]	37（7，149）
HIV载量[M（P25，P75），log拷贝/μl]	9.8（4.7，11.7）
既往HARRT治疗[例（%）]	25（59.5）
血清LDH水平升高[例（%）]	15（35.7）
脑脊液蛋白含量升高[例（%）]	32（76.2）
DLBCL [例（%）]	29（69.0）
深部脑结构受累[例（%）]	22（52.4）
颅内多发病灶[例（%）]	26（61.9）
确诊后放化疗[例（%）]	22（52.4）

表2 AR-PCNSL患者预后的单因素Cox回归分析

因素	β值	危险比（HR）	95%CI	Wald χ²值	P值
年龄	－0.005	0.99	0.96~1.03	0.11	0.745
性别	0.418	1.52	0.20~11.61	0.16	0.687
主诉时间	－0.006	0.99	0.99~1.00	1.68	0.195
KPS评分≥ 70	－1.479	0.23	0.06~0.80	5.32	0.021
既往HARRT治疗	－0.592	0.55	0.21~1.45	1.46	0.227
CD4⁺ T淋巴细胞计数^a	1.238	3.45	0.18~66.00	0.68	0.411
HIV病毒载量^b	0.083	1.09	0.95~1.25	1.68	0.238
LDH含量升高	0.418	1.52	0.58~3.97	0.73	0.394
脑脊液蛋白含量升高	1.663	5.27	0.70~39.92	2.59	0.107
多发病灶	0.674	1.96	0.63~6.10	1.36	0.243
深部脑结构受累	1.067	2.91	0.92~9.17	3.31	0.069
DLBCL	－0.426	0.65	0.24~1.79	0.69	0.407

表2 AR-PCNSL患者预后的单因素Cox回归分析

因素	β值	危险比（HR）	95%CI	Wald χ²值	P值
年龄	－0.005	0.99	0.96~1.03	0.11	0.745
性别	0.418	1.52	0.20~11.61	0.16	0.687
主诉时间	－0.006	0.99	0.99~1.00	1.68	0.195
KPS评分≥ 70	－1.479	0.23	0.06~0.80	5.32	0.021
既往HARRT治疗	－0.592	0.55	0.21~1.45	1.46	0.227
CD4⁺ T淋巴细胞计数^a	1.238	3.45	0.18~66.00	0.68	0.411
HIV病毒载量^b	0.083	1.09	0.95~1.25	1.68	0.238
LDH含量升高	0.418	1.52	0.58~3.97	0.73	0.394
脑脊液蛋白含量升高	1.663	5.27	0.70~39.92	2.59	0.107
多发病灶	0.674	1.96	0.63~6.10	1.36	0.243
深部脑结构受累	1.067	2.91	0.92~9.17	3.31	0.069
DLBCL	－0.426	0.65	0.24~1.79	0.69	0.407

表3 AR-PCNSL患者预后的多因素Cox回归分析

因素	β值	危险比（HR）	95%CI	Wald Z值	P值
KPS评分≥ 70	－1.2518	0.27	0.073~1.000	－1.74	0.012
深部脑结构受累	0.4681	2.42	1.747~7.800	0.68	0.040

表3 AR-PCNSL患者预后的多因素Cox回归分析

因素	β值	危险比（HR）	95%CI	Wald Z值	P值
KPS评分≥ 70	－1.2518	0.27	0.073~1.000	－1.74	0.012
深部脑结构受累	0.4681	2.42	1.747~7.800	0.68	0.040

图2 预后模型的列线图

图3 患者Cox回归模型一年总体生存率的校准曲线

图4 列线图预后模型、MSKCC评分系统不同危险分层及单因素分析的生存曲线

[1]	Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002[J]. AIDS,2006,20(12):1645-1654.
[2]	Dandachi D, Ostrom QT, Chong I, et al. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data[J]. Cancer Causes Control,2019,30(5):477-488.
[3]	Brandsma D, Bromberg J. Primary CNS lymphoma in HIV infection[J]. Handb Clin Neurol,2018,152:177-186.
[4]	Fox CP, Phillips EH, Smith J, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma[J]. Br J Haematol,2019,184(3):348-363.
[5]	You H, Wei L, Kaminska B. Emerging insights into origin and pathobiology of primary central nervous system lymphoma[J]. Cancer Lett,2021,509:121-129.
[6]	Skolasky RL, Dal Pan GJ, Olivi A, et al. HIV-associated primary CNS lymorbidity and utility of brain biopsy[J]. J Neurol Sci,1999,163(1):32-38.
[7]	Binnahil M, Au K, Lu J Q, et al. The influence of corticosteroids on diagnostic accuracy of biopsy for primary central nervous system lymphoma[J]. Can J Neurol Sci,2016,43(5):721-725.
[8]	Gijs PJ, Clerc O. Long-term remission of AIDS-related primary central nervous system lymphoma in a patient under antiretroviral therapy: a case report and review of the literature[J]. AIDS Res Ther,2021,18(1):76.
[9]	Anna C, Valeria B, Silvia G, et al. A case of primary central nervous system lymphoma in advanced naive HIV-infected patient: the role of antiviral agents[J]. AIDS(London, England),2022,36(13):1895-1896.
[10]	Hoang-Xuan K, Deckert M, Ferreri A, et al. European association of neuro-oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)[J]. Neuro Oncol,2023,25(1):37-53.
[11]	Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in Oncology[J]. J Natl Compr Canc Netw,2020,18(11):1537-1570.
[12]	Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience[J]. J Clin Oncol,2003,21(2):266-272.
[13]	Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model[J]. J Clin Oncol,2006,24(36):5711-5715.
[14]	Bayraktar S, Bayraktar UD, Ramos JC, et al. Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors[J]. J Neurooncol,2011,101(2):257-265.
[15]	Lukas RV, Stupp R, Gondi V, et al. Primary central nervous system lymphoma-PART 1: epidemiology, diagnosis, staging, and prognosis[J]. Oncology (Williston Park),2018,32(1):17-22.
[16]	Gupta NK, Nolan A, Omuro A, et al. Long-term survival in AIDS-related primary central nervous system lymphoma[J]. Neuro Oncol,2017,19(1):99-108.
[17]	Moulignier A, Lamirel C, Picard H, et al. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy[J]. Neurology,2017,89(8):796-804.
[18]	International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma[J]. N Engl J Med,1993,329(14):987-994.
[19]	吕亮, 宋玉燕, 张英. HIV感染者原发性中枢神经系统弥漫大B细胞淋巴瘤1例[J]. 皮肤性病诊疗学杂志,2021,28(4):298-301.
[20]	Sakai M, Higashi M, Fujiwara T, et al. MRI imaging features of HIV-related central nervous system diseases: diagnosis by pattern recognition in daily practice[J]. Jpn J Radiol,2021,39(12):1-16.
[21]	秦亚辉, 陈忱, 谭蕾蕾, 等. 原发性中枢神经系统淋巴瘤的临床特点及影像学特征[J]. 中国实用神经疾病杂志,2022,25(1):12-17.
[22]	刘丽欣, 刘景华, 周凡. 原发中枢神经系统淋巴瘤与继发中枢神经系统淋巴瘤的临床特征比较[J]. 解放军医学院学报,2022,43(1):11-14, 19.
[23]	Meling TR, Latysheva A, Da B M, et al. Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?[J]. Neuroradiology, 2018,60(7):703-713.
[24]	Yang C, Ren X, Cui Y, et al. Nomograms for predicting cancer-specific survival in patients with primary central nervous system lymphoma: a population-based analysis[J]. Ann Transl Med,2021,9(13):1055.
[25]	Park SY. Nomogram: An analogue tool to deliver digital knowledge[J]. J Thorac Cardiovasc Surg,2018,155(4):1793.

[1]	张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5]	屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6]	顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[7]	付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[8]	陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[9]	关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10]	张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[11]	陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[12]	韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[13]	董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[14]	王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15]	郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic study of acquired immune deficiency syndrome-related primary central nervous system lymphoma

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic study of acquired immune deficiency syndrome-related primary central nervous system lymphoma